Study of Postoperative ICC Analgesia

Postoperative Analgesia Clinical Trial

— SPICA  

Official title:

Efficacy of Surgically Placed Intercostal Catheter (ICC) for Postoperative Analgesia After Minimally Invasive Anatomical Lung Resection Using Ropivacaine: A Randomised, Double-blind, Placebocontrolled, Superiority Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04939545
• Other study ID #: 2021-00922; kt21Lardinois
• Status: Completed
• Phase: Phase 3
• Start date: December 15, 2021
• Est. completion date: October 20, 2023

Study information

• Verified date: October 2023
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to examine the analgesic effectiveness of continuous loco-regional analgesic application (ropivacaine) through surgically placed Intercostal Catheter (ICC) and to establish correctly this method as a possible standard of care in the postoperative analgesia after Video-assisted thoracoscopic surgery (VATS) anatomical lung resection.

Description:

Good control of the pain without excessive use of opiates supports the benefits of minimally invasive surgical procedure. This study is to examine the efficacy of continuously via surgically placed intercostal catheter administered ropivacaine at a flow rate of 6-8 ml/h of 2 mg/ml on post-operative pain (NRS) and pulmonary function (FEV1, PEF) during a maximum of 72 ± 2 hours after skin closure. Patients undergoing video-assisted thoracoscopic anatomical resection of the lung under general anaesthesia with confirmed or anticipated Stage I Lung cancer will be included. The study will be conducted as superiority, double-blind, placebo-controlled, randomized. The efficacy of loco-regional administered ropivacaine will be compared to placebo (NaCl, 0.9%) administration. The whole study period per participant is expected to be 6 months. In the follow-up, 6 months after surgery, the impact of ropivacaine on long-term pain (NRS, McGill) and pulmonary function (FEV1, PEF) shall be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 20, 2023
• Est. primary completion date: March 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed Consent as documented by signature
• Patient undergoing video-assisted thoracoscopic anatomical resection of the lung under general anaesthesia for confirmed or anticipated Stage I lung cancer (UICC 8th edition)
• American Society of Anesthesiologists (ASA) physical status classes I to III

Exclusion Criteria:

• NRS while coughing > 0
• Previous ipsilateral thoracotomy or sternotomy
• Abdominal or contralateral thoracic surgery up to 6 months preoperatively
• Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product
• Contraindications to self-administration of opioids
• Women who are pregnant or breast feeding
• Chronic steroid therapy (e.g. Prednisone > 10mg/day for more than last 2 weeks before surgery)
• Chronic, daily pain therapy
• Congestive heart failure
• Liver insufficiency
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
• Participation in another study with investigational drug within the 30 days preceding and during the present study,
• Enrolment of the investigator, his/her family members, employees and other dependent person

Related Conditions & MeSH terms

• Postoperative Analgesia

Intervention

Drug:
• Ropivacain
Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated. In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of: ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.
• NaCl 0.9%
Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated. In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of: ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.

Locations

Country	Name	City	State
Switzerland	University Hospital Basel, Department of Thoracic Surgery	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in pain numerical rating scale (NRS) while coughing	change in pain NRS (scale 0-10) while coughing in the Ropivacaine arm compared to Placebo arm; 0 = no pain to 10 = worst pain imaginable	before surgery, at 2, 4, 8, 24, 48, 72 hours after skin closure
Secondary	change in pain NRS at rest	change in pain NRS at rest in the Ropivacaine arm compared to Placebo arm; 0 = no pain to 10 = worst pain imaginable	before surgery, at 2, 4, 8, 24, 48 and 72 hours after skin closure, 1 day before hospital discharge and 6 months ± 28 days after surgery
Secondary	number of daily postoperative pain killer consumption	number of daily postoperative pain killer consumption	within 72 ± 2 hours postoperative
Secondary	change in Silverman integrating approach (SIA) score, combined rank-based analysis of pain score and opioid consumption.	Silverman integrating approach (SIA) score is a combined score from the pain numerical rating scale (NRS) and analgesics (opiate) usage. It is a sum of rank- based percentage differences from the mean rank in pain scores and opioid use, ranging from -200 to 200%. SIA-scores integrate pain scores and opioid use for the individual patient.	within 72 ± 2 hours postoperative
Secondary	change in forced expiratory volume in 1 second (FEV1)	change in forced expiratory volume in 1 second (FEV1)	before surgery, at 24, 48 and 72 hours after skin closure, 1 day before hospital discharge and 6 months ± 28 days after surgery
Secondary	change in peek expiratory flow (PEF)	change in peek expiratory flow (PEF)	before surgery, at 24, 48 and 72 hours after skin closure, 1 day before hospital discharge and 6 months ± 28 days after surgery
Secondary	change in the short-form McGill Questionnaire (SF-MPQ)	The SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The SF-MPQ also includes the Present Pain Intensity (PPI) index of the standard MPQ and a 10 cm visual analogue scale (VAS), 0 = no pain to 10 = worst pain imaginable. The higher the integrated score, the higher the pain level.	before surgery, 48 hours after skin closure and 6 months ± 28 days after surgery
Secondary	Patient Controlled Analgesia (PCA) demand	PCA demand (Consumption of intravenous opiate)	within 72 ± 2 hours postoperative
Secondary	duration of chest tube chest tube	duration of chest tube	within 72 ± 2 hours postoperative
Secondary	length of hospital stay	number of days in hospital postoperative	in the average within 30 days postoperative
Secondary	30 day mortality	30 day mortality	within 30 days postoperative
Secondary	number of gastrointestinal tract events	postoperative nausea and vomiting	within 72 ± 2 hours postoperative
Secondary	time to first defecation	time to first defecation	in the average within 30 days postoperative